Menin inhibitors from monotherapies to combination therapies: clinical trial updates from 2024 ASH annual meeting [0.03%]
ARNI从单药治疗到联合治疗的临床试验进展——2024年ASH年会更新
Gejia Cao,Haixiao Zhang,Shu Sun et al.
Gejia Cao et al.
Menin inhibitors, which target the KMT2A-menin protein-protein interaction to inhibit blasts proliferation and induce differentiation, have demonstrated potential effects on acute leukemia subtypes characterized by overexpression of HOXA ge...
Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic prospects [0.03%]
下一代免疫治疗设计与工具的研究进展：分子机制和转化前景
Hongzhuo Qin,Zhaokai Zhou,Run Shi et al.
Hongzhuo Qin et al.
Immunotherapy has revolutionized the oncology treatment paradigm, and CAR-T cell therapy in particular represents a significant milestone in treating hematological malignancies. Nevertheless, tumor resistance due to target heterogeneity or ...
Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies [0.03%]
司妥昔单抗-替莫卢单药治疗标准疗法耐药的不可切除局部晚期或转移性实体瘤患者的Ib/II期研究结果
Quchang Ouyang,Jordi Rodon,Yan Liang et al.
Quchang Ouyang et al.
Background: Sacituzumab tirumotecan (sac-TMT) is an antibody-drug conjugate composed of an anti-TROP2 monoclonal antibody coupled to a cytotoxic belotecan-derived topoisomerase I inhibitor (KL610023) via a novel linker. W...
Correction: BCMA/GPRC5D bispecific CAR T-cell therapy for relapsed/refractory multiple myeloma with extramedullary disease: a single-center, single-arm, phase 1 trial [0.03%]
纠正：BCMA/GPRC5D 双特异性CAR-T细胞治疗难治性和复发性多发性骨髓瘤伴髓外病变：一项单中心、单组、I期试验
Hao Yao,Shi-Hui Ren,Lin-Hui Wang et al.
Hao Yao et al.
Published Erratum
Journal of hematology & oncology. 2025 Jun 3;18(1):60. DOI:10.1186/s13045-025-01714-1 2025
Integrated clinical and proteomic-based model for diagnostic and prognostic prediction in pRCC [0.03%]
基于临床和蛋白质组的I型透明细胞肾癌诊断和预测模型
Zeya Xu,Linhui Zhang,Jiacheng Lyu et al.
Zeya Xu et al.
Papillary renal cell carcinoma (pRCC), a main pathological subtype of non-clear cell RCC (nccRCC), has strong heterogeneity. Comparing to other nccRCC subtypes, advanced pRCC has the poorest prognosis. Due to its lower incidence compared to...
Panoramic spatial enhanced resolution proteomics (PSERP) reveals tumor architecture and heterogeneity in gliomas [0.03%]
全景空间增强分辨率蛋白质组学（PSERP）揭示了胶质瘤的肿瘤结构和异质性
Ziyan Xu,Yunzhi Wang,Tao Xie et al.
Ziyan Xu et al.
The spatial proteomic profiling of complex tissues is essential for investigating cellular function in physiological and pathological states. However, the imbalance among resolution, protein coverage, and expense precludes their systematic ...
Engineered CRO-CD7 CAR-NK cells derived from pluripotent stem cells avoid fratricide and efficiently suppress human T-cell malignancies [0.03%]
由多能干细胞衍生的工程CRO-CD7 CAR-NK细胞可避免同种相残并有效抑制人类T细胞恶性肿瘤
Yunqing Lin,Ziyun Xiao,Fangxiao Hu et al.
Yunqing Lin et al.
Background: T-cell malignancies are highly aggressive hematological tumors with limited effective treatment options. CAR-NK cell therapy targeting CD7 has emerged as a promising approach for treating T-cell malignancies. ...
BCMA/GPRC5D bispecific CAR T-cell therapy for relapsed/refractory multiple myeloma with extramedullary disease: a single-center, single-arm, phase 1 trial [0.03%]
针对髓外病灶复发/难治多发性骨髓瘤的BCMA/GPRC5D双特异性CAR-T细胞治疗：一项单中心、单组、I期试验
Hao Yao,Shi-Hui Ren,Lin-Hui Wang et al.
Hao Yao et al.
Relapsed/refractory multiple myeloma (RRMM) with extramedullary disease (EMD) represents a challenging condition, with limited treatment options and poor prognosis. We conducted a phase 1 clinical trial to evaluate the safety and effectiven...
Molecular characterization and predictors of relapse in patients with Ph + ALL after frontline ponatinib and blinatumomab [0.03%]
一线 ponatinib 和 blinatumomab 治疗后 Ph+ 急淋白血病患者的分子特征和复发预测因素：报告 CALGB 80702 研究结果
Nicholas J Short,Hagop Kantarjian,Ken Furudate et al.
Nicholas J Short et al.
Background: Several studies have suggested that chemotherapy-free regimens consisting of blinatumomab and a BCR::ABL1 tyrosine kinase inhibitor are highly effective in Philadelphia chromosome-positive acute lymphoblastic ...
Practice-changing updates on multiple myeloma: highlights from the 2024 ASH annual meeting [0.03%]
2024年ASH年会亮点：多发性骨髓瘤的更新及实践改变进展
Ioannis Ntanasis-Stathopoulos,Panagiotis Malandrakis,Maria Gavriatopoulou
Ioannis Ntanasis-Stathopoulos
Although multiple myeloma (MM) remains an incurable disease, the advancements in patient management are rapid and novel approaches emerge each year. At the last congress of the American Society of Hematology (ASH) 2024, several practice-cha...